Publication | Closed Access
162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations
30
Citations
0
References
2010
Year
Tumor BiologyTumor Growth RegardlessNovel Mek 1/2Kras/raf Pathway MutationsMedicineReceptor Tyrosine KinaseCancer Cell BiologyCancer BiologyTumor SuppressorCancer GeneticsRadiation OncologyOncologyCell BiologyCancer ResearchCancer Growth
No additional data available for this publication yet. Check back later!